
Opinion|Videos|January 13, 2025
Second-Line Treatment for R/R Multiple Myeloma: Who Is the “Right Patient”?
Panelists discuss how, for second-line treatment of relapsed/refractory multiple myeloma (R/R MM), patients suitable for CAR T-cell (cilta-cel vs ide-cel) therapy typically have a poor prognosis with limited response to prior therapies. Institutional guidelines focus on factors such as prior lines of therapy, organ function, and cytogenetics. Non-medical factors, such as geographic access and financial constraints, also influence CAR T-cell therapy referral eligibility.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Which patients do you consider for CAR T-cell therapy in second-line treatment for R/R MM (cilta-cel vs ide-cel)?
- Can you describe the specific criteria/institutional guidelines used to determine patient eligibility for CAR T-cell therapy referral?
- How do nonmedical factors (location, money, etc) impact patient selection?
Advertisement
Related to this article

Ajai Chari, MD, discussed sequencing CAR T and bispecifics, fixed-duration therapy, emerging targets, and academic partnership in multiple myeloma.

At the 2026 Chemotherapy Foundation Symposium, Ajai Chari, MD, explained how disease pace and BCMA sequencing guide choosing CAR T or bispecifics.

Ralph V. Boccia, MD, FACP, details the home monitoring tools, prophylaxis, and grade-based approach his practice uses to manage CRS.

Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.

Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.

Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.

Ralph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.
Advertisement
Advertisement
Trending on CancerNetwork
1
Efti Plus Pembrolizumab and RT Yields 81% 12-Month DFS in Soft Tissue Sarcoma
2
Tarlatamab Maintenance Leads the Leaps Forward in Small Cell Lung Cancer
3
Testosterone Therapy Shows No Added Progression Risk in Active Surveillance PCa
4
When to Pause or Stop Therapy in Advanced RCC
5

